In vivo induction of human cytochrome P450 3A4 by rifabutin in chimeric mice with humanized liver

eferences

• Furukawa M, Nishimura M, Ogino D, Chiba R, Ikai I, Ueda N, Naito S, Kuribayashi S, Moustafa MA, Uchida T, et al. Cytochrome p450 gene expression levels in peripheral blood mononuclear cells in comparison with the liver. Cancer Science 2004; 95: 520–529
   PubMed Web of Science ®Google Scholar
• Garcia M, Rager J, Wang Q, Strab R, Hidalgo IJ, Owen A, Li J. Cryopreserved human hepatocytes as alternative in vitro model for cytochrome P450 induction studies. In Vitro Cellular and Developmental Biology Animal 2003; 39: 283–287
   PubMed Web of Science ®Google Scholar
• Gharaibeh MN, Gillen LP, Osborne B, Schwartz JI, Waldman SA. Effect of multiple doses of rifampicin on the [14C N-methyl] erythromycin breath test in healthy male volunteers. Journal of Clinical Pharmacology 1998; 38: 492–495
   PubMed Web of Science ®Google Scholar
• Greuet J, Pichard L, Bonfils C, Domergue J, Maurel P. The fetal specific gene CYP3A7 is inducible by rifampicin in adult human hepatocytes in primary culture. Biochemical and Biophysical Research Communications 1996; 225: 689–694
   PubMed Web of Science ®Google Scholar
• Jamis-Dow CA, Katki AG, Collins JM, Klecker RW. Rifampin and rifabutin and their metabolism by human liver esterases. Xenobiotica 1997; 27: 1015–1024
   PubMed Web of Science ®Google Scholar
• Kast HR, Goodwin B, Tarr PT, Jones SA, Anisfeld AM, Stoltz CM, Tontonoz P, Kliewer S, Willson TM, Edwards PA. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. Journal of Biological Chemistry 2002; 277: 2908–2915
   PubMed Web of Science ®Google Scholar
• Katoh M, Matsui T, Nakajima M, Tateno C, Kataoka M, Soeno Y, Horie T, Iwasaki K, Yoshizato K, Yokoi T. Expression of human cytochromes P450 in chimeric mice with humanized liver. Drug Metabolism and Disposition 2004; 32: 1402–1410
   PubMed Web of Science ®Google Scholar
• Katoh M, Matsui T, Nakajima M, Tateno C, Soeno Y, Horie T, Iwasaki K, Yoshizato K, Yokoi T. In vivo induction of human cytochrome P450 enzymes expressed in chimeric mice with humanized liver. Drug Metabolism and Disposition 2005; 33: 754–763
   PubMed Web of Science ®Google Scholar
• Katoh M, Nakajima M, Shimada N, Yamazaki H, Yokoi T. Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: Prediction of in vivo drug–drug interactions. European Journal of Clinical Pharmacology 2000; 55: 843–852
   PubMed Web of Science ®Google Scholar
• Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680–685
   PubMed Web of Science ®Google Scholar
• Li AP, Maurel P, Gomez-Lechon MJ, Cheng LC, Jurima-Romet M. Preclinical evaluation of drug–drug interaction potential: present status of the application of primary human hepatocytes in the evaluation of cytochrome P450 induction. Chemico-biological Interactions 1997a; 107: 5–16
   PubMed Web of Science ®Google Scholar
• Li AP, Reith MK, Rasmussen A, Gorski JC, Hall SD, Xu L, Kaminski DL, Cheng LK. Primary human hepatocytes as a tool for the evaluation of structure–activity relationship in cytochrome P450 induction potential of xenobiotics: Evaluation of rifampin, rifapentine and rifabutin. Chemico-biological Interactions 1997b; 107: 17–30
   PubMed Web of Science ®Google Scholar
• Liu XG, Narang PK, Li RC. Induction of hepatic and presystemic metabolism of antipyrine in the mice: Rifampicin versus rifabutin. European Journal of Drug Metabolism and Pharmacokinetics 2001; 26: 209–213
   Google Scholar
• Madan A, Graham RA, Carroll KM, Mudra DR, Burton LA, Krueger LA, Downey AD, Czerwinski M, Forster J, Ribadeneira MD, et al. Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metabolism and Disposition 2003; 31: 421–431
   PubMed Web of Science ®Google Scholar
• Matheny CJ, Ali RY, Yang X, Pollack GM. Effect of prototypical inducing agents on P-glycoprotein and CYP3A expression in mouse tissues. Drug Metabolism and Disposition 2004; 32: 1008–1014
   PubMed Web of Science ®Google Scholar
• Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivisto KT. Pharmacokinetic interactions with rifampicin: Clinical relevance. Clinical Pharmacokinetics 2003; 42: 819–850
   PubMed Web of Science ®Google Scholar
• Nishimura M, Naito S, Yokoi T. Tissue-specific mRNA expression profiles of human nuclear receptor subfamilies. Drug Metabolism and Pharmacokinetics 2004; 19: 135–159
   PubMedGoogle Scholar
• Nishimura M, Yoshitsugu H, Naito S, Hiraoka I. Evaluation of gene induction of drug-metabolizing enzymes and transporters in primary culture of human hepatocytes using high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi 2002; 122: 339–361
   PubMed Web of Science ®Google Scholar
• Pascussi JM, Drocourt L, Fabre JM, Maurel P, Vilarem MJ. Dexamethasone induces pregnane X receptor and retinoid X receptor-α expression in human hepatocytes: Synergistic increase of CYP3A4 induction by pregnane X receptor activators. Molecular Pharmacology 2000; 58: 361–372
   PubMed Web of Science ®Google Scholar
• Pascussi JM, Gerbal-Chaloin S, Daujat M, Drocourt L, Pichard-Garcia L, Vilarem MJ, Maurel P, Klieber S, Torreilles F, Bourrie M, et al. CYP gene induction by xenobiotics and drugs. Drug metabolizing enzymes, JS Lee, RS Obach, MB Fisher. Marcel Dekker, New York, NY 2003; 337–374
   Google Scholar
• Perucca E, Grimaldi R, Frigo GM, Sardi A, Mönig H, Ohnhaus EE. Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects. European Journal of Clinical Pharmacology 1988; 34: 595–599
   PubMed Web of Science ®Google Scholar
• Raucy JL, Mueller L, Duan K, Allen SW, Strom S, Lasker JM. Expression and induction of CYP2C P450 enzymes in primary cultures of human hepatocytes. The Journal of Pharmacology and Experimental Therapeutics 2002; 302: 475–482
   PubMed Web of Science ®Google Scholar
• Reinach B, Sousa GD, Dostert P, Ings R, Gugenheim J, Rahmani R. Comparative effects of rifabutin and rifampicin on cytochromes P450 and UDP-glucuronosyl-transferases expression in fresh and cryopreserved human hepatocytes. Chemico-biological Interactions 1999; 121: 37–48
   PubMed Web of Science ®Google Scholar
• Schuetz JD, Beach DL, Guzelian PS. Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver. Pharmacogenetics 1994; 4: 11–20
   PubMedGoogle Scholar
• Strolin BM, Dostert P. Induction and autoinduction properties of rifamycin derivatives: A review of animal and human studies. Environmental Health Perspectives 1994; 102: 101–105
   Google Scholar
• Tateno C, Yoshizane Y, Saito N, Kataoka M, Utoh R, Yamasaki C, Tachibana A, Soeno Y, Asahina K, Hino H, et al. Near completely humanized liver in mice shows human-type metabolic responses to drugs. American Journal of Pathology 2004; 165: 901–912
   PubMed Web of Science ®Google Scholar
• Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annual Review of Pharmacology and Toxicology 1998; 38: 389–430
   PubMed Web of Science ®Google Scholar
• Tomlinson ES, Maggs JL, Park BK, Back DJ. Dexamethasone metabolism in vitro: Species differences. Journal of Steroid Biochemistry and Molecular Biology 1997; 62: 345–352
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Shibata A, Suzuki M, Nakajima M, Shimada N, Guengerich FP, Yokoi T. Oxidation of troglitazone to a quinone-type metabolite catalysed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes. Drug Metabolism and Disposition 1999; 27: 1260–1266
   PubMed Web of Science ®Google Scholar
• Yanagimoto T, Itoh S, Sawada M, Kamataki T. Mouse cytochrome P450 (Cyp3a11): Predominant expression in liver and capacity to activate aflatoxin B1. Archives of Biochemistry and Biophysics 1997; 340: 215–218
   PubMed Web of Science ®Google Scholar